Therapeutic options for mucinous ovarian carcinoma
Kylie L. Gorringe(The University of Melbourne), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Charlie Gourley(Edinburgh Cancer Research), Jan Pyman(Royal Women's Hospital), Timothy Semple(The University of Melbourne), Niko Thio(Peter MacCallum Cancer Centre), Prue E. Allan(Epworth Hospital), Anna DeFazio(The University of Sydney), David D.L. Bowtell(The University of Melbourne), Alison Hadley(The University of Melbourne), Kathryn Alsop(Peter MacCallum Cancer Centre), Richard Lupat(Peter MacCallum Cancer Centre), Yoland Antill(Peninsula Health), Ian Campbell(The University of Sydney), Catherine J. Kennedy(The University of Sydney), Joy Hendley(Peter MacCallum Cancer Centre), Cécile Le Page(Institut Universitaire en Santé Mentale de Québec), Michael Churchman(Edinburgh Cancer Research), Scott H. Kaufmann(Mayo Clinic), Michelle C. Torres(Peter MacCallum Cancer Centre), Sián Fereday(Peter MacCallum Cancer Centre), Georgina L. Ryland(The University of Sydney), Michael Christie(Hudson Institute of Medical Research), Dane Cheasley(The University of Melbourne), Kaushalya Amarasinghe(Peter MacCallum Cancer Centre), Simone M. Rowley(Victorian Clinical Genetics Services), Jessica N. McAlpine(University of British Columbia), Magnus Zethoven(Peter MacCallum Cancer Centre), Martin Köbel(University of Calgary), Sally M. Hunter(Peter MacCallum Cancer Centre), Carolina Salazar(Peter MacCallum Cancer Centre), Orla McNally(Royal Women's Hospital), Jason Li(Queen's University), Andrew N. Stephens(Hudson Institute of Medical Research), Sumitra Ananda(Royal Women's Hospital), C. Blake Gilks(Fox Chase Cancer Center), Yoke-Eng Chiew(Millennium Institute), Nadia Traficante(The University of Melbourne), Hugo Saunders(Peter MacCallum Cancer Centre), Matthew J. Wakefield(The University of Melbourne)
Cited by 95
Related Papers
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k